These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31883832)

  • 21. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
    Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S
    Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis.
    Odaka M; Hasegawa M; Hamaguchi Y; Ishiura N; Kumada S; Matsushita T; Komura K; Sato S; Takehara K; Fujimoto M
    Clin Exp Immunol; 2010 Feb; 159(2):176-84. PubMed ID: 19919568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
    Bei Y; Hua-Huy T; Nicco C; Duong-Quy S; Le-Dong NN; Tiev KP; Chéreau C; Batteux F; Dinh-Xuan AT
    Exp Lung Res; 2016; 42(1):44-55. PubMed ID: 26873329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.
    Morin F; Kavian N; Nicco C; Cerles O; Chéreau C; Batteux F
    J Immunol; 2016 Oct; 197(8):3018-3028. PubMed ID: 27613696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis.
    Maria ATJ; Rozier P; Fonteneau G; Sutra T; Maumus M; Toupet K; Cristol JP; Jorgensen C; Guilpain P; Noël D
    Front Immunol; 2018; 9():3056. PubMed ID: 30622540
    [No Abstract]   [Full Text] [Related]  

  • 26. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
    Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
    Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of marginal zone B cells in CD22-deficient mice.
    Samardzic T; Marinkovic D; Danzer CP; Gerlach J; Nitschke L; Wirth T
    Eur J Immunol; 2002 Feb; 32(2):561-7. PubMed ID: 11828373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages are involved in pathogenesis of bleomycin-induced scleroderma.
    Kato A; Yutani M; Terao M; Kimura A; Itoi S; Murota H; Miyoshi E; Katayama I
    Exp Dermatol; 2015 Aug; 24(8):585-90. PubMed ID: 25876794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of skin fibrosis by RALDH1-producing dermal dendritic cells via retinoic acid-mediated regulatory T cell induction: A role in scleroderma.
    Miura S; Asano Y; Saigusa R; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Sato S; Kadono T
    J Dermatol Sci; 2020 Feb; 97(2):125-134. PubMed ID: 31959382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-21 induction of CD4+ T cell differentiation into Th17 cells contributes to bleomycin-induced fibrosis in mice.
    Lei L; Zhong XN; He ZY; Zhao C; Sun XJ
    Cell Biol Int; 2015 Apr; 39(4):388-99. PubMed ID: 25492803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel bispecific antibody alleviates bleomycin-induced systemic sclerosis injury.
    Yin Q; Pi X; Ren G; Liu Z; Liu H; Wang M; Hu C; Zhao H; Li D; Yin J
    Int Immunopharmacol; 2020 Aug; 85():106644. PubMed ID: 32474387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade.
    Marut W; Kavian N; Servettaz A; Hua-Huy T; Nicco C; Chéreau C; Weill B; Dinh-Xuan AT; Batteux F
    Arthritis Rheum; 2013 May; 65(5):1367-77. PubMed ID: 23335130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.
    Tedder TF; Tuscano J; Sato S; Kehrl JH
    Annu Rev Immunol; 1997; 15():481-504. PubMed ID: 9143697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction.
    Poe JC; Hasegawa M; Tedder TF
    Int Rev Immunol; 2001; 20(6):739-62. PubMed ID: 11913948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress.
    Sekiguchi A; Motegi SI; Fujiwara C; Yamazaki S; Inoue Y; Uchiyama A; Akai R; Iwawaki T; Ishikawa O
    J Dermatol Sci; 2019 Oct; 96(1):8-17. PubMed ID: 31447184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma.
    Mäki-Opas I; Hämäläinen M; Moilanen E; Scotece M
    Arthritis Res Ther; 2023 Jan; 25(1):12. PubMed ID: 36698198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.
    Taniguchi T; Asano Y; Akamata K; Noda S; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S
    Arthritis Rheumatol; 2015 Feb; 67(2):517-26. PubMed ID: 25385187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The B-cell transmembrane protein CD72 binds to and is an in vivo substrate of the protein tyrosine phosphatase SHP-1.
    Wu Y; Nadler MJ; Brennan LA; Gish GD; Timms JF; Fusaki N; Jongstra-Bilen J; Tada N; Pawson T; Wither J; Neel BG; Hozumi N
    Curr Biol; 1998 Sep; 8(18):1009-17. PubMed ID: 9740800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights on chemically induced animal models of systemic sclerosis.
    Batteux F; Kavian N; Servettaz A
    Curr Opin Rheumatol; 2011 Nov; 23(6):511-8. PubMed ID: 21857225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.